Loading stock data…
MASI
$178.48+0.05 (+0.03%)
Market ClosedLast close May 1
Masimo Corporation engages in the development, manufacture, and marketing of various patient monitoring technologies, and automation and connectivity solutions worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Masimo Corporation in the Healthcare sector is trading at $178.48. The stock is currently near its 52-week high of $179.00, remaining 16.9% above its 200-day moving average. Technical signals show neutral RSI of 50 and bearish MACD signal, explaining why MASI maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 50) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$178.48
Potential Downside
88.7%
Whystock Fair Value$20.09
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus3 analysts
Hold
Mean target$180.00+0.9%
Range$180.00 – $180.00
Fundamentals
Masimo Corporation engages in the development, manufacture, and marketing of various patient monitoring technologies, and automation and connectivity solutions worldwide. It offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.36B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
46.78
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.20
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-63.67%
Volume
Today's trading volume
1.01M
Recent News
Danaher Euro Debt Raise Reshapes Masimo Deal And Valuation Story
Danaher (NYSE:DHR) has announced a multi billion euro senior notes offering to fund its planned acquisition of Masimo Corporation. The euro denominated debt issuance is intended to cover the purchase of Masimo and may also support other corporate priorities. The move signals a major capital allocation decision and a planned expansion of Danaher's medical technology footprint. For investors watching NYSE:DHR, this financing decision comes as the share price stands at $178.8 and longer term...
DXCM or MASI: Which Is the Better Value Stock Right Now?
DXCM vs. MASI: Which Stock Is the Better Value Option?
Danaher Corporation (DHR) Reports Q1 Adjusted EPS Beat
Danaher Corporation (NYSE:DHR) is one of the 10 Best Slow Growth Stocks to Buy According to Analysts. On April 21, 2026, Danaher Corporation (NYSE:DHR) reported Q1 adjusted EPS of $2.06, above the $1.94 consensus, with revenue of $6B in line with expectations. Rainer Blair said the company “executed well in the first quarter,” citing nearly […]
Masimo Buyout By Danaher Faces Shareholder Scrutiny On Deal Value
Danaher has agreed to acquire Masimo (NasdaqGS:MASI) in an all cash deal, subject to approval by Masimo shareholders. Several shareholder law firms have announced legal investigations into whether the deal terms and sales process are fair to Masimo investors. The outcome of the shareholder vote and any legal actions could affect the timing, terms, or completion of the transaction. Masimo shares most recently closed at $178.32, with the stock up 40.0% year to date and 15.9% over the past...
3 Small-Cap Stocks Walking a Fine Line
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.